Difficulty: Medium
Average Score: 68%
Practice
A 9-year-old boy develops acute myelogenous leukemia (AML) one year after completion of therapy for soft tissue sarcoma at his right thigh. Which of the following chemotherapeutic agents is MOST likely the cause of secondary acute myelogenous leukemia AML in this boy?
Correct answer
C
Rationale
In this scenario, the correct answer is C) etoposide as the most likely cause of secondary acute myelogenous leukemia (AML) in the 9-year-old boy. Etoposide is a topoisomerase II inhibitor commonly associated with the development of secondary AML as a result of its genotoxic effects on hematopoietic stem cells.
Cyclophosphamide (option A) is an alkylating agent known for causing bladder toxicity and secondary malignancies, but it is not the primary culprit in this case. Vincristine (option B) is a vinca alkaloid that mainly causes peripheral neuropathy and does not typically lead to secondary AML. Doxorubicin (option D) is an anthracycline known for cardiotoxicity, but it is not strongly associated with AML development.
Educationally, understanding the potential long-term complications of chemotherapy agents is crucial for healthcare providers caring for pediatric oncology patients. This case underscores the importance of monitoring patients for secondary malignancies post-chemotherapy and the need for vigilant surveillance for adverse effects of specific chemotherapeutic agents.
Cyclophosphamide (option A) is an alkylating agent known for causing bladder toxicity and secondary malignancies, but it is not the primary culprit in this case. Vincristine (option B) is a vinca alkaloid that mainly causes peripheral neuropathy and does not typically lead to secondary AML. Doxorubicin (option D) is an anthracycline known for cardiotoxicity, but it is not strongly associated with AML development.
Educationally, understanding the potential long-term complications of chemotherapy agents is crucial for healthcare providers caring for pediatric oncology patients. This case underscores the importance of monitoring patients for secondary malignancies post-chemotherapy and the need for vigilant surveillance for adverse effects of specific chemotherapeutic agents.